OXcan uses advanced proteomics measurements and cutting-edge AI to support patient management and care
Our team integrates decades of experience across assay development, proteomic analysis, and respiratory medicine, including chronic obstructive pulmonary disease and lung cancer
We profile the blood plasma proteome in depth, capturing thousands of protein features for each individual patient in one comprehensive molecular analysis
Developed using samples and data from biobanks and large clinical cohorts, our technology reflects biological and population variations seen in real-world lung disease
Disease-linked signal detection in broad data
Proteomic pattern integration with patient context
Alignment with real-world clinical needs
Algorithms informed by lung cancer and respiratory expertise
Protein expression levels are measured from a plasma sample using mass spectrometry. Our AI then analyses these data alongside baseline measurements and clinical expert input to produce a result that can support disease prognosis estimates
A small blood sample is prepared for analysis
Protein levels are evaluated across the sample
Relevant clinical details are added to the analysis
AI interprets disease-linked patterns
Clinicians receive clearer information for risk profiling and disease management
%20(1).svg)